247 related articles for article (PubMed ID: 37424223)
41. Molecular cytogenetic aspects of hematological malignancies: clinical implications.
Chen Z; Sandberg AA
Am J Med Genet; 2002 Oct; 115(3):130-41. PubMed ID: 12407693
[TBL] [Abstract][Full Text] [Related]
42. From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia.
Jakobsen NA; Vyas P
Clin Med (Lond); 2018 Apr; 18(Suppl 2):s47-s53. PubMed ID: 29700093
[TBL] [Abstract][Full Text] [Related]
43. Hematologic Malignancies Discovered on Investigation of Breast Abnormalities.
Alsadi A; Lin D; Alnajar H; Brickman A; Martyn C; Gattuso P
South Med J; 2017 Oct; 110(10):614-620. PubMed ID: 28973700
[TBL] [Abstract][Full Text] [Related]
44. Recurrent Cytogenetic Abnormalities in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.
Ma ES
Methods Mol Biol; 2017; 1541():279-293. PubMed ID: 27910030
[TBL] [Abstract][Full Text] [Related]
45. Therapy resistance mechanisms in hematological malignancies.
Hofmann WK; Trumpp A; Müller-Tidow C
Int J Cancer; 2023 Feb; 152(3):340-347. PubMed ID: 35962946
[TBL] [Abstract][Full Text] [Related]
46. Cytogenetics in the genomic era.
Granada I; Palomo L; Ruiz-Xivillé N; Mallo M; Solé F
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101196. PubMed ID: 33038985
[TBL] [Abstract][Full Text] [Related]
47. WGS and WTS in leukaemia: A tool for diagnostics?
Meggendorfer M; Walter W; Haferlach T
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101190. PubMed ID: 33038979
[TBL] [Abstract][Full Text] [Related]
48. Precision Medicine in Myeloid Malignancies: Hype or Hope?
Upadhyay Banskota S; Khanal N; Marar RI; Dhakal P; Bhatt VR
Curr Hematol Malig Rep; 2022 Dec; 17(6):217-227. PubMed ID: 35972641
[TBL] [Abstract][Full Text] [Related]
49. The DNA methylation landscape of hematological malignancies: an update.
Blecua P; Martinez-Verbo L; Esteller M
Mol Oncol; 2020 Aug; 14(8):1616-1639. PubMed ID: 32526054
[TBL] [Abstract][Full Text] [Related]
50. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
51. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
Miyamoto K; Minami Y
Int J Clin Oncol; 2019 Aug; 24(8):893-898. PubMed ID: 31111287
[TBL] [Abstract][Full Text] [Related]
52. Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies.
Bacher U; Kohlmann A; Haferlach T
Cancer Treat Rev; 2010 Dec; 36(8):637-46. PubMed ID: 20570445
[TBL] [Abstract][Full Text] [Related]
53. Molecular diagnostics in acute leukemias.
Bacher U; Schnittger S; Haferlach C; Haferlach T
Clin Chem Lab Med; 2009; 47(11):1333-41. PubMed ID: 19817644
[TBL] [Abstract][Full Text] [Related]
54. Molecular findings in myeloid neoplasms.
Tran TB; Siddon AJ
Int J Lab Hematol; 2023 Aug; 45(4):442-448. PubMed ID: 37345257
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Diagnostic Yield of a FISH Panel Against Conventional Cytogenetic Studies for Hematological Malignancies: A South Indian Referral Laboratory Analysis Of 201 Cases.
Ashok V; Ranganathan R; Chander S; Damodar S; Bhat S; S NK; A SK; Jadav SS; Rajashekaraiah M; T S S
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3457-3464. PubMed ID: 29286619
[TBL] [Abstract][Full Text] [Related]
56. Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
Peterson JF; Aggarwal N; Smith CA; Gollin SM; Surti U; Rajkovic A; Swerdlow SH; Yatsenko SA
Oncotarget; 2015 Aug; 6(22):18845-62. PubMed ID: 26299921
[TBL] [Abstract][Full Text] [Related]
57. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
58. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.
Duncavage EJ; Bagg A; Hasserjian RP; DiNardo CD; Godley LA; Iacobucci I; Jaiswal S; Malcovati L; Vannucchi AM; Patel KP; Arber DA; Arcila ME; Bejar R; Berliner N; Borowitz MJ; Branford S; Brown AL; Cargo CA; Döhner H; Falini B; Garcia-Manero G; Haferlach T; Hellström-Lindberg E; Kim AS; Klco JM; Komrokji R; Lee-Cheun Loh M; Loghavi S; Mullighan CG; Ogawa S; Orazi A; Papaemmanuil E; Reiter A; Ross DM; Savona M; Shimamura A; Skoda RC; Solé F; Stone RM; Tefferi A; Walter MJ; Wu D; Ebert BL; Cazzola M
Blood; 2022 Nov; 140(21):2228-2247. PubMed ID: 36130297
[TBL] [Abstract][Full Text] [Related]
59. The Potential Roles and Advantages of Single Cell Sequencing in the Diagnosis and Treatment of Hematological Malignancies.
Shi M; Dong X; Huo L; Wei X; Wang F; Sun K
Adv Exp Med Biol; 2018; 1068():119-133. PubMed ID: 29943300
[TBL] [Abstract][Full Text] [Related]
60. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
